Market Overview

Benzinga's Top #PreMarket Gainers

Share:
Related ALNY
5 Biotech Stocks On Deck With The FDA
What's The Street Think Of Alnylam Pharmaceuticals New Drug Data?
Related MRK
Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint
Barron's Recap: Airline Stocks Ready To Soar
Exelixis-Roche's Skin Cancer Drug's FDA Review Delayed - Analyst Blog (Zacks)

Alnylam Pharmaceuticals (NASDAQ: ALNY) shares jumped 35.93% to $90.00 in pre-market trading after the company reported that it has acquired investigational RNAi Therapeutic assets from Merck (NYSE: MRK). Genzyme and Alnylam expanded their collaboration on rare genetic diseases.

Beam (NYSE: BEAM) shares gained 25.93% to $84.35 in the pre-market after the company agreed to be acquired by Suntory Holdings for $83.50 per share in cash.

NII Holdings (NASDAQ: NIHD) surged 20.81% to $2.70 in the pre-market session after the company and Telefonica signed agreements to provide wholesale voice and data services to Nextel in Brazil and Mexico.

Clovis Oncology (NASDAQ: CLVS) soared 6.99% to $79.15 in the pre-market trading after the company announced 2014 objectives and financial outlook.

Posted-In: PreMarket GainersNews Pre-Market Outlook Markets Movers

 

Related Articles (ALNY + BEAM)

Around the Web, We're Loving...

Get Benzinga's Newsletters